TY - JOUR
T1 - Off-label medicine use Ethics, practice and future directions
AU - Bell, J. Simon
AU - Richards, Georgia C.
N1 - Funding Information:
J Simon Bell BPharm (Hons), PhD, MPS, Professor and Director, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Vic Georgia C Richards BSc (Hons), Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, UK Competing interests: JSB reports grants from the National Health and Medical Research Council, the Victorian Government Department of Health and Human Services, the Dementia Australia Research Foundation, the Yulgilbar Foundation, GSK Independent Medical Education Program and aged care provider organisations, outside the submitted work. GCR reports financial support from the National Institute of Health Research (NIHR) School for Primary Care Research (SPCR), the Naji Foundation, and the Rotary Foundation to study for a Doctor of Philosophy (DPhil/PhD) at the University of Oxford. She is also the Editorial Registrar of BMJ Evidence Based Medicine. Funding: None. Provenance and peer review: Not commissioned, externally peer reviewed. Correspondence to: [email protected]
Publisher Copyright:
© The Royal Australian College of General Practitioners
PY - 2021/5
Y1 - 2021/5
N2 - Background Medicine use is considered off-label when used for an indication, at a dose, via a route of administration or in a patient group not included in the approved product information. Off-label use varies according to therapeutic class and patient group, and often occurs in those who are vulnerable. Objective The aim of this article is to discuss ethical, practice and policy considerations associated with off-label medicine use. Discussion A number of professional organisations have issued guidance in relation to offlabel medicine use. Prescribers should inform patients and document consent when prescribing off-label, including an open discussion about known and unknown benefits and risks. It is important that the prescriber documents the reason for off-label use in the patient’s record and ensures that patients are aware of the intended duration and relevant monitoring. Australia’s new national health priority of Quality Use of Medicine and Medicine Safety should stimulate all stakeholders including consumers to work together to address off-label medicine use.
AB - Background Medicine use is considered off-label when used for an indication, at a dose, via a route of administration or in a patient group not included in the approved product information. Off-label use varies according to therapeutic class and patient group, and often occurs in those who are vulnerable. Objective The aim of this article is to discuss ethical, practice and policy considerations associated with off-label medicine use. Discussion A number of professional organisations have issued guidance in relation to offlabel medicine use. Prescribers should inform patients and document consent when prescribing off-label, including an open discussion about known and unknown benefits and risks. It is important that the prescriber documents the reason for off-label use in the patient’s record and ensures that patients are aware of the intended duration and relevant monitoring. Australia’s new national health priority of Quality Use of Medicine and Medicine Safety should stimulate all stakeholders including consumers to work together to address off-label medicine use.
UR - http://www.scopus.com/inward/record.url?scp=85105230193&partnerID=8YFLogxK
U2 - 10.31128/AJGP-08-20-5591
DO - 10.31128/AJGP-08-20-5591
M3 - Article
C2 - 33928284
AN - SCOPUS:85105230193
SN - 2208-794X
VL - 50
SP - 329
EP - 331
JO - Australian Journal of General Practice
JF - Australian Journal of General Practice
IS - 5
ER -